Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
10.55
-0.51 (-4.57%)
At close: Jun 5, 2026, 4:00 PM EDT
10.55
+0.01 (0.05%)
After-hours: Jun 5, 2026, 4:15 PM EDT
Benitec Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
19
Market Cap
362.27M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | - | - | - |
| Jun 30, 2024 | - | - | - |
| Jun 30, 2023 | 75.00K | 2.00K | 2.74% |
| Jun 30, 2022 | 73.00K | 14.00K | 23.73% |
| Jun 30, 2021 | 59.00K | -43.00K | -42.16% |
| Jun 30, 2020 | 102.00K | -12.10M | -99.16% |
| Jun 30, 2019 | 12.20M | 8.81M | 259.85% |
| Jun 30, 2018 | 3.39M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 227.18M |
| Vanda Pharmaceuticals | 217.78M |
| Century Therapeutics | 109.16M |
| OmniAb | 28.94M |
| Prelude Therapeutics | 16.72M |
| X4 Pharmaceuticals | 9.01M |
| Upstream Bio | 3.32M |
| Shattuck Labs | 1.00M |
BNTC News
- 22 days ago - Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update - GlobeNewsWire
- 22 days ago - Benitec Biopharma Earnings release: Q3 2026 - Filings
- 22 days ago - Benitec Biopharma Quarterly report: Q3 2026 - Filings
- 24 days ago - Benitec Biopharma initiated with an Outperform at Evercore ISI - TheFly
- 5 weeks ago - Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting - GlobeNewsWire
- 3 months ago - Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD) - GlobeNewsWire
- 3 months ago - Benitec Biopharma announces interim Phase 1b/2a study of BB-301 - TheFly
- 4 months ago - Benitec Biopharma reports Q2 EPS (26c) vs (26c) last year - TheFly